KR20090115852A - 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 - Google Patents

안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 Download PDF

Info

Publication number
KR20090115852A
KR20090115852A KR1020097017122A KR20097017122A KR20090115852A KR 20090115852 A KR20090115852 A KR 20090115852A KR 1020097017122 A KR1020097017122 A KR 1020097017122A KR 20097017122 A KR20097017122 A KR 20097017122A KR 20090115852 A KR20090115852 A KR 20090115852A
Authority
KR
South Korea
Prior art keywords
peptide
composition
carrier
cargo
pkc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097017122A
Other languages
English (en)
Korean (ko)
Inventor
데렉 맥클린
Original Assignee
카이 파마슈티컬즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카이 파마슈티컬즈 filed Critical 카이 파마슈티컬즈
Publication of KR20090115852A publication Critical patent/KR20090115852A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020097017122A 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 Ceased KR20090115852A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88141907P 2007-01-19 2007-01-19
US60/881,419 2007-01-19
US94528507P 2007-06-20 2007-06-20
US60/945,285 2007-06-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157036605A Division KR101775929B1 (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형

Publications (1)

Publication Number Publication Date
KR20090115852A true KR20090115852A (ko) 2009-11-09

Family

ID=39636771

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197036654A Active KR102274003B1 (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
KR1020157036605A Active KR101775929B1 (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
KR1020177024556A Ceased KR20170104634A (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
KR1020097017122A Ceased KR20090115852A (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020197036654A Active KR102274003B1 (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
KR1020157036605A Active KR101775929B1 (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
KR1020177024556A Ceased KR20170104634A (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형

Country Status (8)

Country Link
US (7) US8067532B2 (https=)
EP (2) EP2109619B1 (https=)
JP (7) JP2010516707A (https=)
KR (4) KR102274003B1 (https=)
CN (3) CN101675067B (https=)
AU (1) AU2008206077A1 (https=)
CA (2) CA2989778C (https=)
WO (1) WO2008089491A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124425A1 (ko) * 2016-12-27 2018-07-05 주식회사 하이센스바이오 신규한 펩타이드

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822302A1 (en) * 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5645408B2 (ja) 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
CA2989778C (en) 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
US20100311671A1 (en) * 2009-03-25 2010-12-09 Kai Pharmaceuticals Transdermal delivery of pkc modulatory peptides through microporated skin
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
HRP20161566T1 (hr) 2011-06-08 2017-02-24 Kai Pharmaceuticals, Inc. Terapijski agensi za reguliranje serumskog fosfora
US20150038435A1 (en) * 2012-03-01 2015-02-05 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
MA38724B1 (fr) * 2013-06-28 2017-11-30 Amgen Inc Formulation liquide stable d'amg 416 (velcalcétide)
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
HK1245671A1 (zh) 2015-05-29 2018-08-31 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
US10981957B2 (en) * 2015-12-02 2021-04-20 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Peptides having antimicrobial activity and new enzyme capable of converting L-configured residue in D-configured amino acid in a peptide
US10654894B2 (en) 2016-02-03 2020-05-19 Keenesaw State University Research And Service Foundation, Inc. Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
US20210330738A1 (en) * 2018-03-29 2021-10-28 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
GB201903873D0 (en) * 2019-03-21 2019-05-08 Univ Nottingham Enhanced transfection
CN114096554A (zh) 2019-07-02 2022-02-25 Ａｇｃ株式会社 肽及其制造方法
JP7725466B2 (ja) 2019-11-13 2025-08-19 アムニクス ファーマシューティカルズ， インコーポレイテッド バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
US20230125482A1 (en) * 2020-03-24 2023-04-27 Young Therapeutics, Llc Protein kinase c modulators
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
EP4406961A4 (en) 2021-09-22 2025-11-05 Agc Inc PEPTIDE
KR102380732B1 (ko) 2021-09-23 2022-04-04 엘이솔루션 주식회사 축산분뇨처리시스템
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615977A (en) * 1898-12-13 Car-fender
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5783405A (en) 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
CN1263473A (zh) * 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 增加跨生物膜转运的组合物和方法
AU741546B2 (en) 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
KR20020081330A (ko) * 2000-02-16 2002-10-26 노오쓰웨스턴 유니버시티 폴리펩토이드 폐 계면활성제
IL137290A0 (en) 2000-07-13 2001-07-24 Asher Eldad Ben An electronic circuit for reducing the danger of exposure to radiation from a transmitter
JP3710368B2 (ja) 2000-09-25 2005-10-26 シャープ株式会社 積層フィルムの製造方法
IL155204A0 (en) 2000-10-02 2003-11-23 Arizeke Pharmaceuticals Inc Compositions and methods for the transport of biologically active agents across cellular barriers
US20020168354A1 (en) * 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
WO2002057413A2 (en) 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20030091640A1 (en) * 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
CA2481979A1 (en) 2002-04-11 2003-10-16 Yasushi Taguchi Peptides chemically modified with polyethylene glycol
JP2005527209A (ja) * 2002-04-22 2005-09-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
CA2506526C (en) * 2002-11-22 2017-04-18 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
EP1597350B1 (en) 2003-02-27 2015-04-08 Yeda Research And Development Co., Ltd. Nucleic acid molecules, and compositions containing same useful for treating and detecting influenza virus infection
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
US7468418B2 (en) * 2003-04-29 2008-12-23 Avi Biopharma., Inc. Compositions for enhancing transport of molecules into cells
CA2549052A1 (en) * 2003-12-11 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
EP1784483A2 (en) 2004-08-02 2007-05-16 The Board Of Trustees Of The Leland Stanford Junior University Peptide sequence for modulation of delta protein kinase c
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
JP4596391B2 (ja) 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
US7767642B2 (en) * 2005-04-15 2010-08-03 Arizona Biomedical Research Commission Therapeutic peptides for the treatment of metastatic cancer
CA2644089A1 (en) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
WO2008042421A2 (en) * 2006-10-02 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the c2 domain of epsilon pkc, and use thereof
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
CA2989778C (en) 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
KR20090117878A (ko) * 2007-01-19 2009-11-13 카이 파마슈티컬즈 통증의 완화를 위한 엡실론 억제제 화합물의 사용 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124425A1 (ko) * 2016-12-27 2018-07-05 주식회사 하이센스바이오 신규한 펩타이드
EP3369741A4 (en) * 2016-12-27 2019-09-18 Hysensbio NOVEL PEPTIDE

Also Published As

Publication number Publication date
KR102274003B1 (ko) 2021-07-08
US20180371448A1 (en) 2018-12-27
CN108948144A (zh) 2018-12-07
CA2989778A1 (en) 2008-07-24
JP2021098725A (ja) 2021-07-01
KR20190140111A (ko) 2019-12-18
US20250034545A1 (en) 2025-01-30
EP3248985A1 (en) 2017-11-29
JP2025185093A (ja) 2025-12-18
WO2008089491A3 (en) 2008-11-27
EP2109619B1 (en) 2017-05-03
KR101775929B1 (ko) 2017-09-07
US20220282239A1 (en) 2022-09-08
KR20160005377A (ko) 2016-01-14
US20120178138A1 (en) 2012-07-12
AU2008206077A1 (en) 2008-07-24
US20090042769A1 (en) 2009-02-12
JP2016147905A (ja) 2016-08-18
EP2109619A4 (en) 2013-04-24
US9255124B2 (en) 2016-02-09
JP2018111717A (ja) 2018-07-19
EP2109619A2 (en) 2009-10-21
CN101675067A (zh) 2010-03-17
CN101675067B (zh) 2013-09-11
CA2989778C (en) 2020-06-30
CA2675665A1 (en) 2008-07-24
JP2010516707A (ja) 2010-05-20
JP2023078424A (ja) 2023-06-06
CA2675665C (en) 2018-02-13
JP5937643B2 (ja) 2016-06-22
US10077438B2 (en) 2018-09-18
WO2008089491A2 (en) 2008-07-24
US8067532B2 (en) 2011-11-29
US20160208237A1 (en) 2016-07-21
EP3248985B1 (en) 2019-10-23
JP2014224126A (ja) 2014-12-04
KR20170104634A (ko) 2017-09-15
US20200370032A1 (en) 2020-11-26
CN103524623A (zh) 2014-01-22

Similar Documents

Publication Publication Date Title
KR102274003B1 (ko) 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
US20200017566A1 (en) Hepcidin and mini-hepcidin analogues and uses therof
US20230158100A1 (en) Treatment of panx1 associates diseases
US10632187B2 (en) Hemagglutinin-binding peptide
CA3022763A1 (en) Novel peptides and peptidomimetics

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090817

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130122

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141028

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150825

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141028

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20151125

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150825

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20160203

Appeal identifier: 2015101006956

Request date: 20151125

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151224

J801 Dismissal of trial

Free format text: TRIAL NUMBER: 2015101006956; REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20151125

Effective date: 20160203

PJ0801 Rejection of trial

Patent event date: 20160203

Patent event code: PJ08011S01D

Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision)

Decision date: 20160203

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2015101006956

Request date: 20151125